Lillie James Woodruff 4

What Happened

• Lillie James Woodruff, Chief Scientific Officer of MapLight Therapeutics, sold 721 shares on May 7, 2026. The filing reports a weighted average sale price of $28.28 per share for total proceeds of $20,390. The transaction is coded as a sale (S) and was an open market or private sale.

Key Details

• Transaction date: May 7, 2026.
• Price: weighted average $28.28; individual sale prices ranged $28.08 to $28.90 (footnote).
• Total proceeds: $20,390 (721 shares × weighted avg $28.28).
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes:
  • F1: Sale made pursuant to a Rule 10b5-1 trading plan adopted Dec 29, 2025.
  • F2: Reported price is a weighted average; the filer will provide breakdown of shares sold at each price on request.
• Filing timeliness: Reported on May 11, 2026 for a May 7 transaction; this filing date is within the SEC’s two-business-day reporting window (timely).

Context

• The sale was executed under a pre-established Rule 10b5-1 plan, which typically schedules trades in advance and can reduce the extent to which a single sale signals the insider’s current view of the company. Sales (like this one) are common and generally less informative than purchases when assessing insider sentiment.